Citations

Mayo Clinic

Showing 10 of 108599 citations.

The Social Media Psyche
Garg, Muskan

Advances in Systems Analysis, Software Engineering, and High Performance Computing | September 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-13

10.4018/978-1-6684-9809-5.ch001 Get It

Amid the pandemic, people express the cause and consequences of their mental disturbance on social media platforms with ease. The causal analysis through cause detection, cause inference, and cause classification, and identifying consequences such as loneliness and low self-esteem expedite the interpersonal risk factors. The interpersonal risk factors of thwarted belongingness and perceived burdensomeness trigger clinical depression, which if left untreated advances to suicidal ideation and self-harm. The mental health practitioners are reliable on mental health triaging and motivational interviewing. To this end, this chapter models the evolution of mental disturbance through self-reported texts generated by users suffering with mental disturbance. The clinical psychology theories on interpersonal needs questionnaire (INQ) supporting a theory on thwarted belongingness and perceived burdensomeness is followed by extracting causes and consequences in a given text.
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022
Veitch, Dallas P. , Weiner, Michael W. , Miller, Melanie J. , Aisen, Paul, Ashford, Miriam A., Harvey, Danielle , Jack, Clifford R. , Jagust, William J. , Landau, Susan, Morris, John C. , Nosheny, Rachel L. , Okonkwo, Ozioma C. , Perrin, Richard J. , Petersen, Ronald C. , Saykin, Andrew J. , Shaw, Leslie M. , Tosun, Duygu , Initiative, for the Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Morris, John C , Harvey, Danielle J , Tosun, Duygu , Ashford, Miriam T. , Beckett, Laurel , Green, Robert C. , Nho, Kwangsik T. , Mindt, Mónica Rivera , Toga, Arthur W. , Initiative, for the Alzheimer's Disease Neuroimaging

Alzheimer's & Dementia | September 12, 2023 | Volume: 20 | Issue: 1 | Pages: 652-694

10.1002/alz.13449 | PMID 37698424 Get It

AbstractThe Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use. Biomarkers of amyloid beta, tau, neurodegeneration, inflammation, and others were prognostic with individualized prediction algorithms available online. Studies supported the amyloid cascade, emphasized the importance of neuroinflammation, and detailed widespread heterogeneity in disease, linked to genetic and vascular risk, co‐pathologies, sex, and resilience. Biological subtypes were consistently observed. Generalizability of ADNI results is limited by lack of cohort diversity, an issue ADNI‐4 aims to address by enrolling a diverse cohort.
CYP2D6 ‐guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial
Mosley, Scott A. , Cicali, Emily J. , Cueto, Alex Del, Portman, Diane , Donovan, Kristine A. , Gong, Yan , Langaee, Taimour , Gopalan, Priya, Schmit, Jessica M., Starr, Jason S. , Silver, Natalie L. , Chang, Young D. , Rajasekhara, Sahana , Smith, Joshua E., Clare‐Salzler, Michael , Starostik, Petr , McLeod, Howard L. , Hicks, J. Kevin , Cicali, Emily , George, Thomas J , Hicks, J Kevin , Cavallari, Larisa H , Soares, Heloisa P. , George, Thomas J. , Fillingim, Roger Benton , Cavallari, Larisa H.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | September 12, 2023 | Volume: 43 | Issue: 12 | Pages: 1286-1296

10.1002/phar.2875 | PMID 37698371 Get It

Abstract Introduction The CYP2D6 enzyme metabolizes opioids commonly prescribed for cancer‐related pain, and CYP2D6 polymorphisms may contribute to variability in opioid response. We evaluated the feasibility of implementing CYP2D6 ‐guided opioid prescribing for patients with cancer and reported pilot outcome data. Methods Adult patients from two cancer centers were prospectively enrolled into a hybrid implementation‐effectiveness clinical trial and randomized to CYP2D6 ‐genotype‐guided opioid selection, with clinical recommendations, or usual care. Implementation metrics, including provider response, medication changes consistent with recommendations, and patient‐reported pain and symptom scores at baseline and up to 8 weeks, were assessed. Results Most (87/114, 76%) patients approached for the study agreed to participate. Of 85 patients randomized, 71% were prescribed oxycodone at baseline. The median (range) time to receive CYP2D6 test results was 10 (3–37) days; 24% of patients had physicians acknowledge genotype results in a clinic note. Among patients with CYP2D6 ‐genotype‐guided recommendations to change therapy ( n = 11), 18% had a change congruent with recommendations. Among patients who completed baseline and follow‐up questionnaires ( n = 48), there was no difference in change in mean composite pain score (−1.01 ± 2.1 vs. −0.41 ± 2.5; p = 0.19) or symptom severity at last follow‐up (3.96 ± 2.18 vs. 3.47 ± 1.78; p = 0.63) between the usual care arm ( n = 26) and genotype‐guided arm ( n = 22), respectively. Conclusion Our study revealed high acceptance of pharmacogenetic testing as part of a clinical trial among patients with cancer pain. However, provider response to genotype‐guided recommendations was low, impacting assessment of pain‐related outcomes. Addressing barriers to utility of pharmacogenetics results and clinical recommendations will be critical for implementation success.
Images in Vascular Medicine: A case of recurrent hemorrhagic bullae from enoxaparin and then fondaparinux
Ghorbanzadeh, Atefeh , Houghton, Damon E. , Houghton, Damon E , Ghorbanzadeh, Atefeh

Vascular Medicine | September 12, 2023 | Volume: 28 | Issue: 6 | Pages: 616-617

10.1177/1358863x231191907 | PMID 37698281 Get It

Piezo channels in stretch effects on developing human airway smooth muscle
Kelley, Brian M. , Zhang, Emily , Khalfaoui, Latifa, Schiliro, Marta, Wells, Natalya M., Pabelick, Christina M. , Prakash, Y. S. , Vogel, Elizabeth R. , Kelley, Brian, Zhang, Emily Y , Wells, Natalya, Prakash, Y S , Pabelick, Christina M , Vogel, Elizabeth R , Kelley, Brian

American Journal of Physiology-Lung Cellular and Molecular Physiology | September 12, 2023 | Volume: 325 | Issue: 5 | Pages: L542-L551

10.1152/ajplung.00008.2023 | PMID 37697925 Get It

Piezo channels were first described just over a decade ago and their function in the lung is largely unknown. We found that piezo channels are present and functional in the developing airway and contribute to intracellular calcium responses and extracellular matrix remodeling in the setting of stretch. This may improve our understanding of the mechanisms behind development of chronic airway diseases, such as asthma, in former preterm infants exposed to respiratory support, such as continuous positive airway pressure (CPAP).
Satisfaction and Feasibility Evaluation of an Electronic Massager—Expert Manipulative Massage Automation (EMMA): A Pilot Study
Yang, Juan , Croghan, Ivana T. , Fokken, Shawn C. , Johnson, Devan E., Calva, Jason J., Do, Alexander , Mueller, Michael , Bauer, Brent A. , Chon, Tony Y.

Journal of Primary Care & Community Health | September 12, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231199010 | PMID 37698255 Get It

Background: Electronic massagers have gained popularity for their non-invasive and cost-effective approach to healthcare. However, existing electronic massagers require manual manipulation, leading to inconsistency. Objective: To investigate the feasibility and acceptability of the Electronic Massager—Expert Manipulative Massage Automation (EMMA) among the American population. Methods: A single-arm pilot study was conducted at Mayo Clinic Rochester campus. Participants received massage therapy with the EMMA treatment model and completed a demographics and Satisfaction Survey Questionnaire. Data were collected using REDCap, and statistical analysis was performed. Results: Twenty healthy volunteers (13 women, 7 men; median age, 47 years) participated and completed the intervention within 2 weeks. No adverse events were reported. Overall, the acceptability and satisfaction of massage utilizing EMMA were high, with all participants finding the study worthwhile, willing to participate again, and willing to recommend the study to others. Regarding the overall experience, 65.0% reported a better-than-expected experience. Responses to open-ended post-treatment questions showed that most participants enjoyed the warmth (35%), pressure (25%), and relaxation (20%) provided by EMMA, with the majority suggesting no changes or improvements were needed. However, some participants expressed a desire for an expanded massage area (20%). Conclusions: This study suggests that the EMMA massager has high acceptability and satisfaction among healthy volunteers, thus demonstrating its feasibility. However, further research is needed to optimize EMMA and assess its clinical effectiveness.
Development of Electronic Health Record-Based Machine Learning Models to Predict Barrett's Esophagus and Esophageal Adenocarcinoma Risk
Iyer, Prasad G. , Sachdeva, Karan , Leggett, Cadman L. , Codipilly, Don C. , Abbas, Halim , Asfahan, Shahir , Awasthi, Samir , Anand, Praveen , Singh, Shiv Pratap , Shukla, Sharad, Bade, Sairam, Mahto, Chandan , Singh, Navjeet , Yadav, Saurav , Padhye, Chinmay, Anderson, Kevin, Anand, Praveen , Leggett, Cadman L , Anderson, Kevin, Kisiel, John B. , Kumar, Praveen M

Clinical and Translational Gastroenterology | September 12, 2023 | Volume: 14 | Issue: 10 | Pages: e00637

10.14309/ctg.0000000000000637 | PMID 37698203 Get It

INTRODUCTION: Screening for Barrett's esophagus (BE) is suggested in those with risk factors, but remains underutilized. BE/esophageal adenocarcinoma (EAC) risk prediction tools integrating multiple risk factors have been described. However, accuracy remains modest (area under the receiver-operating curve [AUROC] ≤0.7), and clinical implementation has been challenging. We aimed to develop machine learning (ML) BE/EAC risk prediction models from an electronic health record (EHR) database. METHODS: The Clinical Data Analytics Platform, a deidentified EHR database of 6 million Mayo Clinic patients, was used to predict BE and EAC risk. BE and EAC cases and controls were identified using International Classification of Diseases codes and augmented curation (natural language processing) techniques applied to clinical, endoscopy, laboratory, and pathology notes. Cases were propensity score matched to 5 independent randomly selected control groups. An ensemble transformer-based ML model architecture was used to develop predictive models. RESULTS: We identified 8,476 BE cases, 1,539 EAC cases, and 252,276 controls. The BE ML transformer model had an overall sensitivity, specificity, and AUROC of 76%, 76%, and 0.84, respectively. The EAC ML transformer model had an overall sensitivity, specificity, and AUROC of 84%, 70%, and 0.84, respectively. Predictors of BE and EAC included conventional risk factors and additional novel factors, such as coronary artery disease, serum triglycerides, and electrolytes. DISCUSSION: ML models developed on an EHR database can predict incident BE and EAC risk with improved accuracy compared with conventional risk factor-based risk scores. Such a model may enable effective implementation of a minimally invasive screening technology.
Immunity in the balance: Fatal disseminated adenovirus infection in a patient undergoing plasma exchange and immunosuppressive chemotherapy for anti‐glomerular basement membrane disease
Jacobs, Jeremy W. , Villalba, Cristina A. Figueroa , Stendahl, Kristin, Tormey, Christopher A. , Abels, Elizabeth , Jacobs, Jeremy W , Tormey, Christopher A , Abels, Elizabeth A

Journal of Clinical Apheresis | September 12, 2023 | Volume: 38 | Issue: 6 | Pages: 770-777

10.1002/jca.22088 | PMID 37698143 Get It

Abstract Anti‐glomerular basement membrane (anti‐GBM) disease (formerly known as Goodpasture's syndrome) is a rare autoinflammatory condition that affects the renal and/or pulmonary capillaries. The standard therapeutic regimen for anti‐GBM disease involves therapeutic plasma exchange (TPE), cyclophosphamide, and corticosteroids to rapidly remove and inhibit autoantibody production and reduce organ inflammation. Herein we report an 82‐year‐old female who developed anti‐GBM disease but expired despite therapy, secondary to multi‐organ failure in the setting of disseminated adenovirus disease. We discuss the utility and potential adverse effect of daily TPE for a protracted course (ie, 10‐14 days), the recommended TPE intensity in the 2023 American Society for Apheresis guidelines, updated from every‐other‐day TPE in the 2019 guidelines, despite no new data. We also highlight the potential for unusual infections to occur in these patients due to the profound immunosuppression, and discuss the importance of balancing immunosuppression to treat the disease with close surveillance of any potential opportunistic infections.
Enhancing Kidney Transplant Care through the Integration of Chatbot
Valencia, Oscar A. Garcia , Jadlowiec, Caroline C. , Mao, Shennen A. , Miao, Jing , Cheungpasitporn, Wisit , Garcia-Valencia, Oscar , Jadlowiec, Caroline , Mao, Shennen A , Miao, Jing , Cheungpasitporn, Wisit , Thongprayoon, Charat

Healthcare | September 12, 2023 | Volume: 11 | Issue: 18 | Pages: 2518

10.3390/healthcare11182518 | PMID 37761715 Get It

Kidney transplantation is a critical treatment option for end-stage kidney disease patients, offering improved quality of life and increased survival rates. However, the complexities of kidney transplant care necessitate continuous advancements in decision making, patient communication, and operational efficiency. This article explores the potential integration of a sophisticated chatbot, an AI-powered conversational agent, to enhance kidney transplant practice and potentially improve patient outcomes. Chatbots and generative AI have shown promising applications in various domains, including healthcare, by simulating human-like interactions and generating contextually appropriate responses. Noteworthy AI models like ChatGPT by OpenAI, BingChat by Microsoft, and Bard AI by Google exhibit significant potential in supporting evidence-based research and healthcare decision making. The integration of chatbots in kidney transplant care may offer transformative possibilities. As a clinical decision support tool, it could provide healthcare professionals with real-time access to medical literature and guidelines, potentially enabling informed decision making and improved knowledge dissemination. Additionally, the chatbot has the potential to facilitate patient education by offering personalized and understandable information, addressing queries, and providing guidance on post-transplant care. Furthermore, under clinician or transplant pharmacist supervision, it has the potential to support post-transplant care and medication management by analyzing patient data, which may lead to tailored recommendations on dosages, monitoring schedules, and potential drug interactions. However, to fully ascertain its effectiveness and safety in these roles, further studies and validation are required. Its integration with existing clinical decision support systems may enhance risk stratification and treatment planning, contributing to more informed and efficient decision making in kidney transplant care. Given the importance of ethical considerations and bias mitigation in AI integration, future studies may evaluate long-term patient outcomes, cost-effectiveness, user experience, and the generalizability of chatbot recommendations. By addressing these factors and potentially leveraging AI capabilities, the integration of chatbots in kidney transplant care holds promise for potentially improving patient outcomes, enhancing decision making, and fostering the equitable and responsible use of AI in healthcare.
Expedited Laparoscopic Cholangiogram and Liver Biopsy in the Workup of Biliary Atresia
Lai, Krista , Wadera, Sheetal, Jamshidi, Ramin , Lee, Justin , Padilla, Benjamin E. , Garvey, Erin M., Notrica, David M. , Eldredge, R Scott

Journal of Pediatric Gastroenterology and Nutrition | September 12, 2023 | Volume: 77 | Issue: 6 | Pages: No page available

10.1097/mpg.0000000000003943 | PMID 37697468 Get It

Purpose:Recent studies demonstrate the success of Kasai portoenterostomy for biliary atresia (BA) is linearly related to infant age at time of Kasai. We sought to review the feasibility and safety of laparoscopic needle micropuncture cholangiogram with concurrent core liver biopsy (if needed) for expedited exclusion of BA in patients with direct conjugated hyperbilirubinemia.Methods:Expedited laparoscopic cholangiogram and liver biopsy were instituted at our facility for infants with direct hyperbilirubinemia for whom clinical exam and laboratory workup failed to diagnose. A retrospective chart review was performed in infants <1 year with hyperbilirubinemia from 2016 to 2021. Demographics, preoperative evaluation, procedure details, and complications were reviewed.Results:Two hundred ninety‐seven infants with unspecified jaundice were identified, of which, 86 (29%) required liver biopsy. Forty‐seven percutaneous liver biopsies were obtained including 8 (17%) in whom BA could not be excluded. Laparoscopic cholangiogram was attempted in 47 infants following basic workup; BA was diagnosed in 22 infants (47%) of which 3 were <18 days old. Biliary patency was demonstrated laparoscopically in 22 of 25 (88%); 3 (12%) required conversion to open cholangiogram. Infants with percutaneous liver biopsy had an average delay of 3 days (range: 2–36) to cholangiogram. Preoperative studies and liver biopsy alone did not reliably exclude the diagnosis of BA.Conclusion:Laparoscopic cholangiogram with liver biopsy is a safe procedure resulting in the confirmation or exclusion of BA in infants. Forty‐seven percent of infants who underwent laparoscopic cholangiogram were found to have BA; those who were surgical candidates underwent Kasai during the same operation.